Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACtiVe trial of MesoPher after resection of pancreatic cancer
2018-003222-92Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Nov 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MesoPher in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Erasmus MC. Primary endpoint: Feasibility of MesoPher administration. Started Nov 2018; status: completed.
02
Drugs
MesoPher
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2018-003222-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003222-92.